Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: N05CH

Hetlioz(tasimelteon)

Sleep Disorders, Circadian Rhythm

Marketing Authorisation Holder: Vanda Pharmaceuticals Netherlands B.V.

EMA Authorisation: 03/07/2015

INN: tasimelteon

Indication

Hetlioz is indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Hetlioz — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.